CFVR≤2.0 n=425 | 2<CFVR ≤2.5 n=593 | CFVR>2.5 n=666 | P value* | |
Classic chest pain classification, n (%) | ||||
Typical AP | 84 (19.8) | 118 (19.9) | 154 (23.1) | 0.104 |
Atypical AP | 208 (48.9) | 288 (48.6) | 279 (41.9) | |
Non-cardiac chest pain | 133 (31.3) | 187 (31.5) | 233 (35.0) | |
Rose’s Angina Questionnaire, n (%) | ||||
Severe definite AP | 80 (19.9) | 98 (17.8) | 126 (20.0) | 0.850 |
Non-severe definite AP | 102 (25.4) | 138 (25.0) | 159 (25.3) | |
Non-definite AP | 220 (54.7) | 316 (57.2) | 344 (54.7) | |
Seattle Angina Questionnaire, mean (SD) | ||||
Physical limitation | 70.2 (22.5) | 74.0 (23.0) | 76.2 (22.7) | <0.001 |
Angina stability | 62.3 (28.3) | 63.0 (28.4) | 63.9 (27.8) | 0.133 |
Angina frequency | 75.1 (27.1) | 76.2 (28.4) | 76.4 (26.1) | 0.177 |
Treatment satisfaction | 67.6 (38.7) | 66.2 (39.3) | 66.5 (25.5) | 0.656 |
Perception/quality of life | 53.7 (21.6) | 54.6 (21.1) | 54.0 (22.1) | 0.230 |
Further chest pain classification, n (%) | ||||
Chest discomfort at exertion | 84 (20.8) | 109 (19.2) | 103 (16.3) | 0.285 |
Chest discomfort at rest | 139 (34.5) | 204 (35.9) | 250 (39.6) | |
Chest discomfort at exertion and rest | 180 (44.7) | 255 (44.9) | 279 (44.1) | |
Chest discomfort during dipyridamole intravenous | 118 (29.4) | 179 (31.1) | 194 (30.0) | 0.580 |
Reproduced symptoms during dipyridamole | 98 (24.9) | 145 (25.8) | 152 (23.9) | 0.401 |
Weekly chest discomfort | 252 (59.3) | 311 (52.4) | 380 (57.1) | 0.614 |
*P value from age-adjusted trend test (logistic or linear regression analysis) or χ2 test when the independent variable is divided into three categories.
AP, angina pectoris.